首页> 外文期刊>The Journal of molecular diagnostics: JMD >Diagnosis of Primary Ciliary Dyskinesia by a Targeted Next-Generation Sequencing Panel Molecular and Clinical Findings in Italian Patients
【24h】

Diagnosis of Primary Ciliary Dyskinesia by a Targeted Next-Generation Sequencing Panel Molecular and Clinical Findings in Italian Patients

机译:有针对性的下一代测序专家组对意大利患者原发性睫状运动障碍的诊断

获取原文
获取原文并翻译 | 示例
           

摘要

Primary ciliary dyskinesia (PCD) is a rare genetic disorder that alters mucociliary clearance, with consequent chronic disease of upper and lower airways. Diagnosis of PCD is challenging, and genetic testing is hampered by the high heterogeneity of the disease, because autosomal recessive causative mutations were found in 34 different genes. In this study, we clinically and molecularly characterized a cohort of 51 Italian patients with clinical signs of PCD. A custom next-generation sequencing panel that enables the affordable and simultaneous screening of 24 PCD genes was developed for genetic analysis. After variant filtering and prioritization, the molecular diagnosis of PCD was achieved in 43% of the patients. Overall, 5 homozygous and 27 compound heterozygous mutations, 21 of which were never reported before, were identified in 11 PCD genes. The DNAH 5 and DNAH11 genes were the most common cause of PCD in Italy, but some population specificities were identified. In addition, the number of unsolved cases and the identification of only a single mutation in six patients suggest further genetic heterogeneity and invoke the need of novel strategies to detect unconventional pathogenic DNA variants. Finally, despite the availability of mutation databases and in silica prediction tools helping the interpretation of variants in next-generation sequencing screenings, a comprehensive segregation analysis is required to establish the in trans inheritance and support the pathogenic role of mutations.
机译:原发性睫状运动障碍(PCD)是一种罕见的遗传疾病,可改变粘膜纤毛清除率,从而导致上下呼吸道慢性疾病。 PCD的诊断具有挑战性,并且疾病的高度异质性阻碍了基因检测,因为在34个不同的基因中发现了常染色体隐性病因突变。在这项研究中,我们在临床和分子上对51名患有PCD临床体征的意大利患者进行了研究。开发了一个定制的下一代测序小组,该小组使得能够以负担得起的方式同时筛选24种PCD基因,以进行遗传分析。经过变量过滤和优先排序后,在43%的患者中实现了PCD的分子诊断。总体而言,在11个PCD基因中鉴定出5个纯合子和27个复合杂合子突变,其中21个以前从未报道过。 DNAH 5和DNAH11基因是意大利引起PCD的最常见原因,但已鉴定出一些种群特异性。此外,未解决病例的数量和六名患者中仅单个突变的鉴定提示了进一步的遗传异质性,并引发了对检测非常规致病性DNA变异的新颖策略的需求。最后,尽管有突变数据库和二氧化硅预测工具可帮助下一代测序筛选中的变体解释,但仍需要进行全面的分离分析以建立反式遗传并支持突变的致病作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号